ArticleScience translational medicine2024
Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age-related tauopathy and Alzheimer's disease.
Abstract read
In one paragraph
Article in Science translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Article
- Plasma eMTBR-tau243 as a disease biomarker across Alzheimer's disease clinical phenotypes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- A probabilistic framework for clinicopathological Alzheimer's disease using tau-PET.Alzheimer's research & therapy · 2026Article
- Correlation between in vivoAlzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Association of [Neurology · 2026Article
- Distinct tau filament folds in familial frontotemporal dementia due to thebioRxiv : the preprint server for biology · 2026Article
- The Role of Amyloid-β and Tau PET in the New Era of Alzheimer Disease Therapies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Review
- Posterior cortical atrophy and logopenic variant primary progressive aphasia are more specific for Alzheimer's disease pathology than probable Alzheimer's disease.Brain communications · 2026Article
- Quantitation of PET spatial extent as a potential adjunct to visual interpretation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Primary age-related tauopathy.Acta neuropathologica · 2025Review
- Article
- Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex.Nature neuroscience · 2025Article
- An integrated view of the relationships between amyloid, tau, and inflammatory pathophysiology in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Tau burden is best captured by magnitude and extent: Tau-MaX as a measure of global tau.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- White matter hyperintensities in dementia with lewy bodies and posterior cortical atrophy.Neurobiology of aging · 2025Article
- Integrative network analysis reveals novel moderators of Aβ-Tau interaction in Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- Fully individualized models for cross-sectional and longitudinal network-based tau spread.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- Investigating the feasibility ofAlzheimer's & dementia : the journal of the Alzheimer's Association · 2024Observational
- The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP-TAU study.Alzheimer's research & therapy · 2024Article
- Association of in vivo retention of [Acta neuropathologica · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Keith A JosephsDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-2930-8634
Nirubol TosakulwongDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-2385-6835
Stephen D WeigandDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Christopher G SchwarzDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-1466-8357
Matthew L SenjemDepartment of Information Technology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-9308-9275
Mary M MachuldaDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-4834-5967
Kejal KantarciDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-8001-2081
David S KnopmanDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-6544-066X
Aivi NguyenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-1809-9451
R Ross ReichardDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0001-7189-7917
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-8178-6601
Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-7916-622X
Jennifer L WhitwellDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Funding
SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6MResearch Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5MLongitudinal multi-modality imaging in progressive apraxia of speech (Diversity Supplement)R01DC012519 · NIDCD · MAYO CLINIC ROCHESTER · PI Jennifer Louise Whitwell · 2013 to 2026
$7.2MDisease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8MUnderstanding the role of TDP-43 in Alzheimers disease and FTLDR01AG037491 · NIA · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A · 2010 to 2024
$6.5MMolecular and structural imaging in atypical Alzheimer's disease: a longitudinal studyR01AG050603 · NIA · MAYO CLINIC ROCHESTER · PI WHITWELL, JENNIFER LOUISE · 2016 to 2025
$5.9MLongitudinal Multi-modal Imaging in Progressive Supranuclear Palsy SyndromesR01NS089757 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, WHITWELL, JENNIFER LOUISE · 2015 to 2024
$5.6MThe neurobiology of two distinct types of progressive apraxia of speechR01DC014942 · NIDCD · MAYO CLINIC ROCHESTER · PI Keith A Josephs, Rene Lynn Utianski · 2017 to 2026
$4.9MFlortaucipir PET and histopathology in frontotemporal lobar degeneration and Alzheimer’s diseaseRF1NS112153 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, WHITWELL, JENNIFER LOUISE · 2021 to 2021
$1.2MFlortaucipir PET and histopathology in frontotemporal lobar degeneration and Alzheimer’s diseaseR01NS112153 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, WHITWELL, JENNIFER LOUISE · 2024 to 2025
$767kNIA NIH HHS P30 AG062677NIA NIH HHS R01 AG037491NIA NIH HHS R01 AG050603NIA NIH HHS R37 AG011378NIA NIH HHS U01 AG006786NIDCD NIH HHS R01 DC012519NIDCD NIH HHS R01 DC014942NINDS NIH HHS R01 NS089757NINDS NIH HHS R01 NS112153NINDS NIH HHS RF1 NS112153
Abstract
[
Indexed as
Alzheimer DiseaseAmyloid beta-PeptidesCarbolinesPositron-Emission TomographyTauopathiestau ProteinsAgedAged, 80 and overBrainFemaleHumansMaleMiddle Aged7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleAmyloid beta-PeptidesCarbolinestau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.